Yoshimi Maehiro

Alternating venetoclax/azacytidine and FLT3 inhibitor treatment for NPM1- and FLT3-mutated acute myeloid leukemia.

H. Ozawa, K. Nagafuji, K. Aoyama, 2023, Leukemia research.

High-dose cytarabine plus gemtuzumab ozogamicin as consolidation therapy in patients with favorable- or intermediate-risk acute myeloid leukemia.

Satoshi Morishige, Takayuki Nakamura, Fumihiko Mouri, 2024, International journal of hematology.